ORIC ORIC Pharmaceuticals, Inc. Stock Quote

ORIC [NASD]

Index	-	P/E	-	EPS (ttm)	-1.59	Insider Own	1.16%	Shs Outstand	30.32M	Perf Week	4.20%
Market Cap	1.39B	Forward P/E	-	EPS next Y	-2.14	Insider Trans	0.00%	Shs Float	18.11M	Perf Month	21.49%
Income	-53.80M	PEG	-	EPS next Q	-0.46	Inst Own	97.00%	Short Float	18.88%	Perf Quarter	6.87%
Sales	-	P/S	-	EPS this Y	-25.80%	Inst Trans	28.49%	Short Ratio	10.92	Perf Half Y	44.67%
Book/sh	6.08	P/B	5.96	EPS next Y	41.20%	ROA	-	Target Price	44.14	Perf Year	-
Cash/sh	4.87	P/C	7.44	EPS next 5Y	-	ROE	-	52W Range	18.60 - 40.81	Perf YTD	7.06%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-11.20%	Beta	-
Dividend %	-	Quick Ratio	27.30	Sales past 5Y	-	Gross Margin	-	52W Low	94.84%	ATR	2.83
Employees	60	Current Ratio	27.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	57.40	Volatility	10.31% 8.48%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	75.00%	Profit Margin	-	Rel Volume	0.75	Prev Close	34.29
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	313.07K	Price	36.24
Recom	1.60	SMA20	6.98%	SMA50	6.18%	SMA200	26.11%	Volume	233,374	Change	5.69%

Jan-25-21

Downgrade

Citigroup

Buy → Neutral

$34

Aug-13-20

Initiated

Robert W. Baird

Outperform

$45

Aug-06-20

Upgrade

Citigroup

Neutral → Buy

$35

Aug-03-20

Initiated

H.C. Wainwright

Buy

$52

May-19-20

Initiated

JP Morgan

Overweight

$40

May-19-20

Initiated

Jefferies

Buy

$40

May-19-20

Initiated

Guggenheim

Buy

$45

May-19-20

Initiated

Citigroup

Neutral

$35

Mar-02-21 06:30AM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Feb-17-21 12:15PM	Spiking Yields Pierce Bonds & Growth Stocks ETF.com
Feb-03-21 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Feb-02-21 04:04AM	How Much Of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Do Institutions Own? Simply Wall St.
Jan-11-21 06:30AM	ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones GlobeNewswire
Jan-08-21 10:35AM	Oppenheimer: These 3 Stocks Could Spike Over 80% TipRanks
Jan-04-21 06:30AM	ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-20 06:30AM	ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101 GlobeNewswire
Dec-10-20 04:50PM	Is ORIC A Good Stock To Buy Now? Insider Monkey
Dec-01-20 08:30AM	ORIC Pharmaceuticals (ORIC) in Focus: Stock Moves 6.7% Higher Zacks
Nov-17-20 04:15PM	ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Nov-13-20 06:32AM	ORIC Pharmaceuticals Announces Pricing of Upsized Public Offering GlobeNewswire
Nov-10-20 04:05PM	ORIC Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Nov-09-20 06:30AM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-05-20 04:05PM	ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update GlobeNewswire
Nov-04-20 10:43AM	ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +6.01%
Oct-19-20 04:02PM	ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program GlobeNewswire
Oct-09-20 06:30AM	ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020 GlobeNewswire
Sep-02-20 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-06-20 03:50PM	What Kind Of Investors Own Most Of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)? Simply Wall St. +14.07%
Aug-05-20 04:10PM	ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update GlobeNewswire
04:05PM	ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics GlobeNewswire
Aug-03-20 10:15PM	ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call GlobeNewswire +9.87%
Jun-22-20 09:00AM	ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II GlobeNewswire -6.95%
Jun-09-20 04:15PM	ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors GlobeNewswire -5.15%
May-27-20 06:30AM	ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II GlobeNewswire
May-26-20 06:30AM	ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference GlobeNewswire
May-20-20 04:15PM	ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results GlobeNewswire -9.75%
Apr-28-20 04:30PM	ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-27-20 04:30PM	ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting GlobeNewswire
Apr-23-20 08:56PM	ORIC Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience